Quantum Chemical Studies of Bendamustine and Melphalan in Water as Antiblood Cancer Agents

Quantum Chemical Studies of Bendamustine and Melphalan in Water as Antiblood Cancer Agents

Saved in:

Bibliographic Details
Main Authors:	Roman Boča, Juraj Štofko, Miriam Ladická, Cyril Rajnák
Format:	Article
Language:	English
Published:	American Chemical Society 2024-12-01
Series:	ACS Omega
Online Access:	https://doi.org/10.1021/acsomega.4c08646
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Quantum Chemical Studies of Anti-Blood Cancer Agents, II
by: Roman Boča, et al.
Published: (2025-05-01)

Quantum chemical study of molecular properties of small branched-chain amino acids in water
by: Roman Boča, et al.
Published: (2025-01-01)

Electronic Properties of Small Psychotropic Substances in WaterPhenylamines
by: Roman Boča, et al.
Published: (2025-08-01)

Molecular properties of linear amino acids in water
by: Roman Boča, et al.
Published: (2024-02-01)

SYNTHESIS OF BENDAMUSTINE HYDROCHLORIDE IN FLOW MICROREACTOR
by: A. Moldavsky, et al.
Published: (2019-01-01)

Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice
by: Nisha V. Shah, et al.
Published: (2014-01-01)

Intravitreal Melphalan Chemotherapy for Vitreous Seeds in Retinoblastoma
by: Yacoub A. Yousef, et al.
Published: (2020-01-01)

Experience with the use of bendamustine (Rozustin®): safety and efficacy
by: A. A. Semenova, et al.
Published: (2020-10-01)

New Approaches to Improving Bendamustine Microractor Synthesis
by: A. L. Moldavsky, et al.
Published: (2020-02-01)

Melphalan delivery and co-delivery nanoformulations for cancer therapy: A comprehensive review
by: Hamidreza Abdouss, et al.
Published: (2024-12-01)

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
by: Crystal Mackall, et al.
Published: (2024-07-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Bendamustine: a new view on treatment of chronic lymphocytic leukemia
by: Ye. A. Nikitin
Published: (2022-11-01)

Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation
by: Dan Xie, et al.
Published: (2025-02-01)

Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab
by: Wulyo Rajabto, et al.
Published: (2024-07-01)

Comparison of the adsorption behavior of melphalan anti-cancer drug on MgS nano-cage: A DFT study
by: Shahnaz Azari Gharelar, et al.
Published: (2025-05-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Repeated use of hybrid isolated chemoperfusion with melphalan in non-resectable liver malignancy
by: A. I. Babich, et al.
Published: (2024-03-01)

A pilot study of intraoperative melphalan to prevent recurrent PVR: the IOMPVR study
by: Carlos A. Moreira-Neto, et al.
Published: (2025-05-01)

Isolated chemohyperthermal perfusion of the liver with melphalan in the treatment of unresectable liver metastases with uveal melanoma
by: A. D. Kaprin, et al.
Published: (2021-12-01)

Crystal Structure of Melphalan Hydrochloride and Its Association with Caffeine Improves Its Antineoplastic Action
by: Juliana Pereira da Silva, et al.
Published: (2025-05-01)

NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma
by: Debora Soncini, et al.
Published: (2025-03-01)

BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.
by: Roberto Castelli
Published: (2016-07-01)

Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.
by: Chengyu Wu, et al.
Published: (2024-01-01)

BRAIN-INVOLVED MULTIPLE MYELOMA: STABILITY ACHIEVED WITH BENDAMUSTINE-POMALIDOMIDE, RADIOTHERAPY AND DARATUMUMAB-BASED THERAPY
by: Bengisu Ece Duman, et al.
Published: (2024-12-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Retinal changes after intravitreal injections of various concentrations of antiproliferative medication Melphalan: an experimental and morphological study
by: I. P. Khoroshilova-Maslova, et al.
Published: (2018-10-01)

Obinutuzumab combined with bendamustine for the treatment of hairy cell leukemia variant: a case report and literature review
by: Junjun Bai, et al.
Published: (2025-08-01)

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
by: Michael A. Lane, et al.
Published: (2015-01-01)

A QUANTUM CHEMICAL STUDY OF THE CONFORMATION OF ALINIDINE A NEW ANTIARRHYTHMIC AGENT
Published: (1991-12-01)

Chemical environment of water molecules adsorbed on the anatase surface: quantum chemical study
by: O. V. Smirnova, et al.
Published: (2019-05-01)

Vibration energy harvesting by ferrofluids in external magnetic fields
by: Michal Rajnak, et al.
Published: (2025-07-01)

Quantum Chemical Mass Spectral Predictions of Novichok Agents after Experimental Validation and Analysis
by: Sungsoo Kim, et al.
Published: (2025-05-01)

Pharmacokinetics and outcome of high-dose melphalan followed by autologous stem cell transplantation in dialysis-dependent patients with multiple myeloma
by: Rabea Mecklenbrauck, et al.
Published: (2025-01-01)

Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
by: Sara Bringhen, et al.
Published: (2025-07-01)

Correction: Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery.
by: Manuel Florian Struck, et al.
Published: (2024-01-01)

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database
by: Fang Wu, et al.
Published: (2025-02-01)

Effect of Acalabrutinib in Combination with Bendamustine plus Rituximab on Survival Endpoints in Older Patients with Mantle Cell Lymphoma: Insights from the ECHO Trial
by: Adrian Schmidt
Published: (2024-12-01)

Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large B-cell lymphoma
by: Enguang Bi, et al.
Published: (2024-11-01)

Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia
by: YuV Mirolyubova, et al.
Published: (2018-04-01)